Search results
The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer.
21 cze 2006 · In this initial report of the STAR trial, raloxifene and tamoxifen were equivalent in efficacy for lowering the risk of invasive breast cancer. The cumulative incidence rates were 25.1 per 1000 women (raloxifene) vs 24.8 per 1000 (tamoxifen) (P = .83).
5 cze 2006 · STAR is a study that compared the drugs tamoxifen and raloxifene in reducing the risk of breast cancer in postmenopausal women at increased risk of the disease. The study found that both drugs were equally effective, but raloxifene had fewer side effects.
Cancer Prevention Trial (BCPT), the STAR trial is one of the largest prospective trials that enrolled women with proliferative breast lesions, with more than 9% having a personal history of LCIS and 22.7% having either atypical ductal or lobular hyperplasia on a previous breast biopsy (T able 1). The mean predicted
1 maj 2006 · One of the largest breast cancer prevention clinical trials ever conducted, STAR enrolled 19,747 postmenopausal women who were at increased risk of the disease. Participants were randomly assigned to receive either 60 mg of raloxifene or 20 mg of tamoxifen daily for 5 years.
12 paź 2006 · The National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial recently demonstrated that raloxifene, a selective estrogen-receptor modulator, was as...
9 lis 2010 · The STAR trial was a randomized, double-blinded study that enrolled 19,747 postmenopausal women from July 1999 to November 2004 who were 35 years or older with a 5-year Gail model risk of 1.66% or higher or a personal history of LCIS . Women that met the eligibility criteria were randomized to receive either tamoxifen 20 mg and placebo or ...
